Economics, Pharma, Policy and politics 11/1/16 Economics, Pharma, Policy and politics 11/1/16 PCSK9 experience shows drug market isn't completely broken Read More Devices, Economics, Pharma, Policy and politics 9/30/16 Devices, Economics, Pharma, Policy and politics 9/30/16 Justifying EpiPen pricing, once again Read More Economics, Health plans, Uncategorized 8/18/16 Economics, Health plans, Uncategorized 8/18/16 Surprise, surprise! Exchange customers are price sensitive Read More Economics, Policy and politics 7/8/16 Economics, Policy and politics 7/8/16 Dialysis and its discontents Read More Culture, Economics, Technology 6/6/16 Culture, Economics, Technology 6/6/16 In the future, will every job be a healthcare job? Read More Economics, Health plans, Uncategorized 5/31/16 Economics, Health plans, Uncategorized 5/31/16 Will Zika help or hurt health plans? Read More Economics, Pharma, Policy and politics, Uncategorized 5/11/16 Economics, Pharma, Policy and politics, Uncategorized 5/11/16 Biosimilars are "me-too" drugs, not generics Read More Economics 5/10/16 Economics 5/10/16 Due diligence in middle market healthcare investing Read More Economics, Health plans, Hospitals, Uncategorized 4/19/16 Economics, Health plans, Hospitals, Uncategorized 4/19/16 Urgent care billing: Eyebrows raised Read More Economics, Entrepreneurs, Pharma, Policy and politics 12/17/15 Economics, Entrepreneurs, Pharma, Policy and politics 12/17/15 How Martin Shkreli is driving down drug prices Read More Economics, Hospitals 12/1/15 Economics, Hospitals 12/1/15 Joslin Diabetes CEO faces 'big challenges' --I'm quoted Read More Economics, Hospitals, Patients 10/7/15 Economics, Hospitals, Patients 10/7/15 What can we do about overuse of emergency rooms? Read More Economics, Hospitals 8/27/15 Economics, Hospitals 8/27/15 Massachusetts hospitals are making money -- I'm quoted Read More Economics 8/19/15 Economics 8/19/15 Wal-Mart provides evidence Obamacare is working Read More Economics, Pharma 7/27/15 Economics, Pharma 7/27/15 Four reasons Praluent is not Sovaldi Read More Economics, Pharma, Policy and politics 7/20/15 Economics, Pharma, Policy and politics 7/20/15 Follow-on biologics: Another ho-hum assessment Read More Economics, Research 6/17/15 Economics, Research 6/17/15 Long term care insurance --narrow framing is not the problem Read More Culture, Economics, Pharma, Policy and politics 5/7/15 Culture, Economics, Pharma, Policy and politics 5/7/15 What's the difference between New York and Boston? Read More Culture, Economics, Pharma 4/7/15 Culture, Economics, Pharma 4/7/15 Cancer drugs: Why the high and rising prices? Read More Economics, Medical travel/medical..., Patients, Pharma, Policy and politics 3/18/15 Economics, Medical travel/medical..., Patients, Pharma, Policy and politics 3/18/15 Sovaldi: a near-perfect example of price discrimination Read More Newer Posts Older Posts
Economics, Pharma, Policy and politics 11/1/16 Economics, Pharma, Policy and politics 11/1/16 PCSK9 experience shows drug market isn't completely broken Read More
Devices, Economics, Pharma, Policy and politics 9/30/16 Devices, Economics, Pharma, Policy and politics 9/30/16 Justifying EpiPen pricing, once again Read More
Economics, Health plans, Uncategorized 8/18/16 Economics, Health plans, Uncategorized 8/18/16 Surprise, surprise! Exchange customers are price sensitive Read More
Economics, Policy and politics 7/8/16 Economics, Policy and politics 7/8/16 Dialysis and its discontents Read More
Culture, Economics, Technology 6/6/16 Culture, Economics, Technology 6/6/16 In the future, will every job be a healthcare job? Read More
Economics, Health plans, Uncategorized 5/31/16 Economics, Health plans, Uncategorized 5/31/16 Will Zika help or hurt health plans? Read More
Economics, Pharma, Policy and politics, Uncategorized 5/11/16 Economics, Pharma, Policy and politics, Uncategorized 5/11/16 Biosimilars are "me-too" drugs, not generics Read More
Economics, Health plans, Hospitals, Uncategorized 4/19/16 Economics, Health plans, Hospitals, Uncategorized 4/19/16 Urgent care billing: Eyebrows raised Read More
Economics, Entrepreneurs, Pharma, Policy and politics 12/17/15 Economics, Entrepreneurs, Pharma, Policy and politics 12/17/15 How Martin Shkreli is driving down drug prices Read More
Economics, Hospitals 12/1/15 Economics, Hospitals 12/1/15 Joslin Diabetes CEO faces 'big challenges' --I'm quoted Read More
Economics, Hospitals, Patients 10/7/15 Economics, Hospitals, Patients 10/7/15 What can we do about overuse of emergency rooms? Read More
Economics, Hospitals 8/27/15 Economics, Hospitals 8/27/15 Massachusetts hospitals are making money -- I'm quoted Read More
Economics, Pharma, Policy and politics 7/20/15 Economics, Pharma, Policy and politics 7/20/15 Follow-on biologics: Another ho-hum assessment Read More
Economics, Research 6/17/15 Economics, Research 6/17/15 Long term care insurance --narrow framing is not the problem Read More
Culture, Economics, Pharma, Policy and politics 5/7/15 Culture, Economics, Pharma, Policy and politics 5/7/15 What's the difference between New York and Boston? Read More
Culture, Economics, Pharma 4/7/15 Culture, Economics, Pharma 4/7/15 Cancer drugs: Why the high and rising prices? Read More
Economics, Medical travel/medical..., Patients, Pharma, Policy and politics 3/18/15 Economics, Medical travel/medical..., Patients, Pharma, Policy and politics 3/18/15 Sovaldi: a near-perfect example of price discrimination Read More
